Table 1 Demographic and clinical characteristics of patients.

From: Unravelling the genetic and molecular basis of low-frequency rTMS induced changes in functional connectivity density in schizophrenia patients with auditory verbal hallucinations

 

Active group(n = 30)

Placebo group (n = 25)

t(χ2)

p

Age

30.30 ± 4.46

31.46 ± 6.35

0.644

0.478

Gender (female)

17 (13)

14(12)

0.045

0.832

Education (years)

13.20 ± 2.67

12.81 ± 2.71

0.458

0.756

Duration of illness (month)

21.36 ± 4.89

20.35 ± 3.38

0.525

0.602

Dosage (CPED, mg/day)

584.8 ± 152.39

573.46 ± 136.88

0.218

0.828

PANSS

    

Positive symptom

19.65 ± 4.60

18.65 ± 3.36

0.983

0.330

Negative symptom

19.85 ± 4.53

19.35 ± 3.02

0.178

0.860

General symptom

40.35 ± 6.65

39.50 ± 4.62

0.537

0.593

AHRS

27.45 ± 6.14

25.73 ± 5.08

0.689

0.494

  1. PANSS positive and negative symptoms; AHRS auditory hallucination rating scale. CPED Chlorpromazine equivalent doses.
Back to article page